Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real‐life setting: A multicentre prospective study

Respirology ◽  
2019 ◽  
Vol 25 (5) ◽  
pp. 535-542 ◽  
Author(s):  
Luca Rinaldi ◽  
Stefania Milione ◽  
Maria Chiara Fascione ◽  
Pia Clara Pafundi ◽  
Concetta Altruda ◽  
...  
Keyword(s):  
Prospective Study ◽  
Respiratory Diseases ◽  
Lung Ultrasound ◽  
Real Life ◽  
Diagnostic Algorithm ◽  
Real Life Setting ◽  
Multicentre Prospective Study

scholarly journals Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Konstantinos Gourgoulianis ◽  
Alessandro Ruggieri ◽  
Alessandra del Vecchio ◽  
Fabrizio Calisti ◽  
Alessandro Comandini ◽  
...  
Keyword(s):  
Prospective Study ◽  
Chronic Bronchitis ◽  
Real Life ◽  
Routine Care ◽  
Symptom Improvement ◽  
Type I ◽  
Real World Evidence ◽  
Acute Exacerbations ◽  
Sputum Volume ◽  
Multicentre Prospective Study

Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile.

MANAGEMENT OF RESECTION OF LARGE COLONIC LESIONS IN A REAL-LIFE SETTING: THE SCALP STUDY

2018 ◽  
Author(s):  
A Amato ◽  
F Radaelli ◽  
V Cennamo ◽  
E Di Giulio ◽  
L Fuccio ◽  
...  
Keyword(s):  
Real Life ◽  
Real Life Setting

130-LB: Retrospective Evaluation of Treatment Patterns in a Real-Life Setting Environment with Dapagliflozin or DPP-4 Inhibitors as Add-On Therapy in Uncontrolled DM2 Patients Who Previously Failed on Other Regimens

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 130-LB
Author(s):  
DIEGO ESPINOZA-PERALTA ◽  
ARNULFO GONZÁLEZ-CANTÚ ◽  
ALEJANDRA I. SILVA ◽  
JUAN G. COLLADO ◽  
JORGE DAVID ROGEL-MANZANARES ◽  
...  
Keyword(s):  
Real Life ◽  
Treatment Patterns ◽  
Retrospective Evaluation ◽  
Real Life Setting
Sign in / Sign up

Export Citation Format

Share Document